Could gene edits solve obstacles to treatment for the most common types of cancer?

Since 2017, a personalized immunotherapy called Chimeric Antigen Receptor, or CAR-T cell treatment, has worked wonders to treat patients with blood cancers such as leukemia. But when it comes to treating solid tumor cancers, such as lung, breast and kidney cancers that make up the bulk of these malignancies, this type of immune cell therapy has fallen short.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup